Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01264471
Other study ID # H09378
Secondary ID GW080138
Status Completed
Phase N/A
First received December 17, 2010
Last updated April 10, 2015
Start date May 2009
Est. completion date June 2013

Study information

Verified date April 2015
Source Medical Neurogenetics, LLC
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Observational

Clinical Trial Summary

The purpose of the study is to investigate possible causes for Gulf War Syndrome. Gulf War Syndrome is associated with increased incidences of amyotrophic lateral sclerosis (Lou Gehrig's Disease), pain syndromes, muscle complaints that include fatigue and myalgias (muscle pain), as well as other neurological symptoms. Abnormalities in the part of the cell known as mitochondria have been delineated in Gulf War Syndrome. Mitochondria are the "power plants" of the body. Mitochondria take the food you eat and break the food down into a form of energy that the body can use. The investigators propose that Gulf War Syndrome is determined by a complex interaction of factors that interfere with mitochondrial function. This study will be the first investigation of mitochondrial function in Gulf War Syndrome. The investigators objective is to establish the cause for symptoms in affected veterans, develop testing that can more easily identify Gulf War Syndrome, and ultimately develop treatment protocols for Gulf War Syndrome.


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date June 2013
Est. primary completion date June 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Short-term memory loss or a severe inability to concentrate that affects work, school or other normal activities

- Muscle Pain, myalgias

- Pain without redness or swelling in a number of joints

- Intense or changing patterns of headaches

- Unrefreshing sleep

- After any exertion, weariness that lasts for more than a day

Exclusion Criteria:

- Organ failure (e.g. emphysema, cirrhosis, cardiac failure, chronic renal failure)

- Chronic infections (e.g. HIV/AIDS, hepatitis B or C)

- Rheumatic and chronic inflammatory diseases (e.g. systemic lupus erythematosis, Sjogren's syndrome, rheumatoid arthritis, inflammatory bowel disease, chronic pancreatitis.)

- Major neurologic diseases (e.g. multiple sclerosis, neuromuscular diseases, epilepsy or other disease requiring ongoing medication that could cause fatigue, stroke, head injury with residual neurologic deficits)

- Diseases requiring systemic treatment (e.g. organ or bone marrow transplantation; systemic chemotherapy; radiation of brain, thorax, abdomen, or pelvis)

- Major endocrine diseases (e.g. hypopituitarism, adrenal insufficiency)

- Myocardial infarction, heart failure

- Morbid obesity (body mass index >40)

- Permanent psychiatric exclusions: Lifetime diagnoses of bipolar affective disorders, schizophrenia or any subtype, delusional disorders of any subtype, dementias of any subtype, organic brain disorders, and alcohol or substance abuse within 2 years before onset of the fatiguing illness.

- History of allergic reaction to lidocaine

- History of keloid formation with skin incisions.

Study Design

Observational Model: Case-Only, Time Perspective: Cross-Sectional


Intervention

Procedure:
Skin biopsy
A small skin sample will be obtained from the patients arm which is approximately the size of the top of a thumbtack (a small circle no more than a 1/4 inch across)
Blood Collection
Approximately 45ml or 3 tablespoons for blood will be drawn from a vein in the patient's forearm.

Locations

Country Name City State
United States Medical Neurogenetics, LLC Atlanta Georgia

Sponsors (2)

Lead Sponsor Collaborator
Medical Neurogenetics, LLC United States Department of Defense

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Characterize mitochondrial cellular energetics in Gulf War Syndrome patients After collecting a skin and blood sample, mitochondrial cellular energetics in Gulf War Syndrome patients will be characterized by: 1. high resolution respirometry of intact cells, 2. quantitative analysis of individual mitochondrial proteins, 3. analysis of intact OXPHOS enzyme complexes and supercomplexes, 4. in gel enzyme activity assessment of intact OXPHOS enzyme complexes and supercomplexes, 5. mitochondrial DNA (mtDNA) copy number quantitation to assess for defects in regulation mtDNA replication and 6. cellular coenzyme Q10 quantitation. approximately 2 years; once all data has been collected from study participants No
Secondary Mitochondrial DNA Assess the mitochondrial DNA (mtDNA) from each patient with Gulf War Syndrome for mtDNA mutations by whole genome sequencing of leukocyte and skin cell mtDNA. approximately 2 years; once all data has been collected from study participants. No
See also
  Status Clinical Trial Phase
Completed NCT00129454 - Telemedicine Treatment for Veterans With Gulf War Illness N/A
Completed NCT00100412 - Hyporeactivity and Gulf War Illness N/A
Recruiting NCT04182659 - Long Term Efficacy of Neuronavigation Guided rTMS in Alleviating Gulf War Illness Related Headaches and Pain Symptoms N/A
Recruiting NCT04987775 - GWICTIC: NAC Mechanistic Study in Gulf War Veterans Early Phase 1
Completed NCT03342482 - Glutamate Neuro-Excitotoxicity in GWI N/A
Terminated NCT03547869 - Transcranial Direct Current Stimulation for Pain Treatment in Gulf War Illness. N/A
Recruiting NCT05675878 - Confirmation of Diet as a Treatment for Gulf War Illness Phase 3
Recruiting NCT05736146 - Validating Gulf War Illness Blood Biomarkers
Completed NCT03560830 - START & STOPP in GWI
Recruiting NCT05355272 - Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT) Phase 2
Terminated NCT04712071 - Ketamine in Veterans With Gulf War Illness Early Phase 1
Completed NCT03030794 - Alleviating Headache and Pain in GWI With Neuronavigation Guided rTMS N/A
Completed NCT04638998 - Assessing Neuroinflammation in GWI Using MRS
Completed NCT02804828 - Mitochondrial Cocktail for Gulf War Illness N/A
Recruiting NCT02848417 - Glutathione vs. Curcumin Clinical Trial Phase 1/Phase 2
Recruiting NCT00956150 - Bacterial Overgrowth Associated With Chronic Multisymptom Illness Complex Phase 1
Completed NCT00018707 - Follow-up of Psychological and Neurocognitive Gulf War Outcome: Relation to Stress N/A
Not yet recruiting NCT05992311 - Clinical Evaluation of Montelukast in Veterans With Gulf War Illness Phase 1